Venomyx Therapeutics careers

Our first product addresses the highly underserved snake antivenom market.

In 2018, 5.5 Million people around the world will be bitten by a venomous snake.150,000 of them will die and many thousands more will be permanently disabled.

In May of this year, the WHO identified snakebite as a top global health priority. It continues to be one of the world's most neglected public health issues.

Conventional antivenom is made today the same way it has been made for over a century! Venom must be obtained from the snakes and injected into horses to generate antibodies which are then injected into the human patient.

At Venomyx, we are developing the world's first broad-spectrum and fully recombinant antivenom to serve the $1B global snake envenomation market. Our antivenom can be manufactured at scale in bacteria and administered in the field for the first time ever.

The epi-pen for snakebite!